Novel immune engagers and cellular therapies for metastatic castration-resistant prostate cancer: do we take a BiTe or ride BiKEs, TriKEs, and CARs?

Published in: Prostate cancer and prostatic diseases (2021)

Multiple immune engagers and cell therapies are in the development pipeline and demonstrate promise to address barriers to better outcomes for metastatic castration-resistant prostate cancer patients.

Keyphrases

squamous cell carcinoma
end stage renal disease
small cell lung cancer
newly diagnosed
ejection fraction
chronic kidney disease
single cell
stem cells
peritoneal dialysis
type diabetes
metabolic syndrome
machine learning
skeletal muscle
deep learning